Matinas BioPharma
MTNB
47 hedge funds and large institutions have $27.7M invested in Matinas BioPharma in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 12 closing their positions.
0.09% less ownership
Funds ownership: 0.54% → 0.45% (-0.09%)
13% less funds holding
Funds holding: 54 → 47 (-7)
33% less capital invested
Capital invested by funds: $41.1M → $27.7M (-$13.4M)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 2 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$192K |
| 3 |
Bank of New York Mellon
New York
|
+$94.7K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$74.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$52.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.88M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.29M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$1.14M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$991K |
| 5 |
Millennium Management
New York
|
-$382K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TEE
51
Tibra Equities Europe
London,
United Kingdom
| – | -$264K | -4,839 | Closed |
|
52
Barclays
London,
United Kingdom
| – | -$65K | -1,353 | Closed |
|
53
Goldman Sachs
New York
| – | -$66K | -1,208 | Closed |
|
|
ECM
54
ExodusPoint Capital Management
New York
| – | -$42K | -764 | Closed |
|
55
Bank of America
Charlotte,
North Carolina
| – | -$34K | -622 | Closed |
|
56
UBS Group
Zurich,
Switzerland
| – | -$12K | -216 | Closed |
|
|
AIC
57
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$6K | -112 | Closed |
|
|
CHP
58
Cable Hill Partners
Portland,
Oregon
| – | -$1K | -20 | Closed |
|
MTNB Hedge Fund Activity: Q2 2019 in Review
47 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2019, worth a combined $27.7M — down 33% from $41.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MTNB and 5 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $1.36M. The largest seller was Broadfin Capital, cutting an estimated $1.88M.
- 47 institutional investors held Matinas BioPharma (MTNB) as of Q2 2019, down from 54 in Q1 2019.
- Funds reported $27.7M of Matinas BioPharma stock for Q2 2019, down 33% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q2 2019 and 12 closed out, a net change of -7 holders.
- The largest Matinas BioPharma buyer in Q2 2019 was Vanguard Group, an estimated $1.36M added.
- The largest Matinas BioPharma seller in Q2 2019 was Broadfin Capital, an estimated $1.88M sold.
Based on aggregated 13F filings for Q2 2019.